Fractyl Health’s GLP-1 gene therapy trial given green light

Fractyl believes its AAV GLP-1 gene therapy is the first of its kind to enter clinical trials. Fractyl believes its AAV GLP-1 gene therapy is the first of its kind to enter clinical trials. The gene therapy is going into a first-in-human trial in the Netherlands. Credit: Andrii Yalanskyi / Shutterstock.com Fractyl Health’s trial to evaluate a glucagon-like peptide-1 (GLP-1) gene therapy has been approved by European authorities. The open-label, first-in-human, Phase I/II study will investigate RJVA-001 in patients with obesity and type 2 diabetes. LOA and PTSR Model Froniglutide [Inn] in Becker Muscular Dystrophy Reports LOA and PTSR…

Source: Clinical Trials Arena